RAMAT GAN, Israel, June 26,
2024 /PRNewswire/ -- Medasense, a global leader in pain
monitoring solutions, is proud to announce a strategic partnership
with Nihon Kohden for the exclusive distribution of its
revolutionary pain monitoring device in Japan. This partnership is intended to
transform pain management practices across Japanese healthcare
facilities, offering a significant advancement in patient care.
Nihon Kohden, renowned for its history of excellence in
providing innovative high quality, reliable medical technology that
improves the way healthcare is practiced, is partnering with
Medasense to introduce its nociception monitor to the Japanese
market. This cutting-edge device, with its state-of-the-art AI
powered NOL - Nociception Level Index®, provides real-time,
objective pain monitoring, enabling the personalization and
optimization of pain treatment. It will be accessible to hospitals
and clinics throughout Japan
through Nihon Kohden's extensive distribution channels pending
regulatory approval.
Medasense's CEO & Founder, Galit
Zuckerman, expressed enthusiasm about the collaboration: "We
are honored to partner with Nihon Kohden, a company with a long
history of excellence, that shares our vision of improving patient
care through innovative solutions. Our mission is to help all
patients suffer less from pain and the adverse effects of pain
medication. Nihon Kohden's established clinical, technological
leadership and expertise in the Japanese market make them the
perfect partner to distribute our nociception monitor."
NOL monitoring provides an AI powered, clinically validated
index to objectively quantify the physiological response to pain
(nociception) supporting clinicians in delivering personalized
anesthesia tailored to patient requirements. With over 40 peer
reviewed publications, clinical studies have demonstrated that
NOL-guided analgesia resulted in intraoperative opioid sparing, and
improved post operative pain scores and patient
recovery.1,2
For more information about Medasense and Nihon Kohden, please
visit www.medasense.com and www.nihonkohden.com/.
About Medasense and NOL – Nociception Level Index®
Technology
Medasense is transforming pain management with its breakthrough
technology that empowers clinicians to optimize and personalize
pain control, significantly reducing the risk of pain or of
overmedication. The company's flagship product, the PMD-200™,
equipped with the NOL-Nociception Level Index®, leverages advanced
artificial intelligence and a proprietary non-invasive sensor
system. This unique platform provides objective monitoring and
quantification of a patient's pain response, making it an essential
tool in an operating room and critical care unit settings where
patients cannot communicate their pain levels. The PMD-200 is the
first and only monitor to be authorized by the FDA for pain
measurement for anaesthesiology. It has been used in over
100,000 surgeries worldwide, and is commercially available in the
US, Europe, Canada, Latin
America and Israel.
Watch Medasense's 1-minute video
About Nihon Kohden
Founded in 1951, Nihon Kohden is a global leader of medical
solutions with the goal to improve healthcare with advanced
technology. For more than 70 years, Nihon Kohden has continued to
provide a wide range of medical electronic equipment including EEG,
EMG/EP measuring systems, electrocardiographs, bedside monitors,
defibrillators, AEDs, ventilators, and hematology
instruments.
Nihon Kohden utilizes cutting-edge technology to support medical
treatment in all clinical areas, integrating medical devices into
the IT network to meet customers' requirements and offers a wide,
comprehensive solution.
For further information please contact:
Rachel Weissbrod, VP Clinical &
Market Development, Medasense
+972-54-544-9115
rachel@medasense.com
1. Meijer, F., Honing, M., Roor, T., Toet, S., Calis, P.,
Olofsen, E., Martini, C., van Velzen, M., Aarts, L., Niesters, M.,
Boon, M., Dahan, A. (2020). Reduced postoperative pain using
Nociception Level-guided fentanyl dosing during sevoflurane
anaesthesia: a randomised controlled trial. British Journal of
Anaesthesia, In Press.
DOI:https://doi.org/10.1016/j.bja.2020.07.057
2. Fleur S. Meijer,
Chris H. Martini, Suzanne Broens, Martijn
Boon, Marieke Niesters, Leon
Aarts, Erik Olofsen, Monique van
Velzen, Albert Dahan.
Nociception-guided versus Standard Care during
Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial.
Anesthesiology (2019); 130:745–755
Logo:
https://mma.prnewswire.com/media/1169999/Medasense_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/medasense-announces-a-strategic-agreement-with-global-medical-company-nihon-kohden-corporation-302183281.html